| 摘要 |
The present invention is directed towards the use and delivery of a therapeutic method and agent to reduce and prevent excessive scarring resulting from cellular contraction and/or excess accumulation of extracellular matrix by inhibition and/or inducement of smooth muscle actin (SMA) and/or tissue growth factor beta (TGF-beta) in a tissue, organ or injury site.
|
